NDA 212839 · Sk Life
Xcopri
Cenobamate · Oral
NovelLast checked: Nov 19, 2026Latest source record: Aug 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Nov 21, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
19
7 Phase 3, 3 recruiting
FAERS reports
8,531
3,375 serious, 208 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 25, 2025.
XCOPRI is indicated for the treatment of partial-onset seizures in adult patients. XCOPRI is indicated for the treatment of partial-onset seizures in adult patients. ( 1 )
Mechanism: The precise mechanism by which cenobamate exerts its therapeutic effects in patients with partial-onset seizures is unknown. Cenobamate has been demonstrated to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid (GABA A ) ion channel.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
6 products under this application
- XCOPRI · CENOBAMATE 200MG · TABLET, ORAL · Prescription
- XCOPRI · CENOBAMATE 100MG · TABLET, ORAL · Prescription
- XCOPRI · CENOBAMATE 25MG · TABLET, ORAL · Prescription
- XCOPRI · CENOBAMATE 150MG · TABLET, ORAL · Prescription
- XCOPRI · CENOBAMATE 50MG · TABLET, ORAL · Prescription
- XCOPRI · CENOBAMATE 12.5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cenobamate" as an intervention, any sponsor and status, largest first.
- Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresPivotal-lookingCompleted
SK Life Science, Inc.Industry
NCT02535091 · 1,345 participants · Start Aug 3, 2016 · Primary completion Mar 31, 2021
Drug: YKP3089 · For: Partial Epilepsy
Sites: Phoenix, Arizona; Little Rock, Arkansas; Anaheim, California · 121 sites in all
- Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POSPivotal-lookingCompleted
SK Life Science, Inc.Industry
NCT04557085 · 519 participants · Start Mar 8, 2021 · Primary completion Feb 16, 2024
Drug: Cenobamate; Placebo · For: Partial Seizure; Focal Seizure
Sites: Shanghai, China; Tokyo, Japan; Seoul, South Korea
- A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset SeizuresPivotal-lookingCompleted
SK Life Science, Inc.Industry
NCT01866111 · 437 participants · Start Jul 31, 2013 · Primary completion Apr 5, 2021
Drug: YKP3089; Placebo · For: Partial Epilepsy
Sites: Phoenix, Arizona; Little Rock, Arkansas; Anaheim, California · 67 sites in all
- Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset SeizuresPivotal-lookingCompleted
SK Life Science, Inc.Industry
NCT01397968 · 222 participants · Start Jul 6, 2011 · Primary completion Jun 2013
Drug: YKP3089; Placebo · For: Partial Epilepsy
Sites: Phoenix, Arizona; Little Rock, Arkansas; Anaheim, California · 38 sites in all
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC SeizuresPivotal-lookingCompleted
SK Life Science, Inc.Industry
NCT03678753 · 169 participants · Start Oct 3, 2018 · Primary completion May 26, 2025
Drug: Cenobamate; Placebo · For: Primary Generalized Epilepsy
Sites: Phoenix, Arizona; Tuscon, Arizona; Fresno, California · 116 sites in all
- Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) SeizuresPivotal-lookingCompleted
SK Life Science, Inc.Industry
NCT05067634 · 154 participants · Start Jan 10, 2022 · Primary completion Oct 2, 2026
Drug: Xcopri · For: Partial Epilepsy
Sites: Phoenix, Arizona; Palo Alto, California; Hartford, Connecticut · 35 sites in all
- Cenobamate Open-Label Extension Study for YKP3089C025Pivotal-lookingCompleted
SK Life Science, Inc.Industry
NCT03961568 · 147 participants · Start Aug 13, 2019 · Primary completion Jun 10, 2026
Drug: Cenobamate · For: Primary Generalized Tonic Clonic Seizures in the Setting of Idiopathic Generalized Epilepsy
Sites: La Jolla, California; Miami, Florida; Tampa, Florida · 45 sites in all
Ono Pharmaceutical Co., Ltd.Industry
NCT06590896 · 100 participants (planned) · Start Nov 4, 2022 · Primary completion Jan 31, 2027
Drug: Cenobamate · For: Epilepsies, Partial
Sites: Ehime, Japan; Fukushima, Japan; Hiroshima, Japan · 29 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure2,543
- product dose omission issue1,880
- fatigue845
- somnolence823
- off label use691
- dizziness668
- product use issue608
- fall470
- headache391
- wrong technique in product usage process382
- drug ineffective380
- drug interaction364
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 5 |
| 2020 | 84 |
| 2021 | 1,679 |
| 2022 | 612 |
| 2023 | 558 |
| 2024 | 1,527 |
| 2025 | 2,057 |
| 2026 | 2,009 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xcopri (Cenobamate)
2024 spending
$165M
Beneficiaries
12,500
117,028 claims
Per beneficiary
$13,176
$38.43 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,577,855 |
| 2021 | $32,547,978 |
| 2022 | $68,154,842 |
| 2023 | $113,076,802 |
| 2024 | $164,703,013 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cenobamate add-on therapy for drug-resistant focal epilepsy.
Brigo F, Lattanzi S · Cochrane Database Syst Rev 2024 · Meta-Analysis, Systematic Review
- Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.
Krauss GL, Klein P, Brandt C, et al. · Lancet Neurol 2020 · Multicenter Study, Randomized Controlled Trial
- Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures.
Chung SS, French JA, Kowalski J, et al. · Neurology 2020 · Clinical Trial, Phase II, Multicenter Study
- Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis.
Lattanzi S, Trinka E, Zaccara G, et al. · Drugs 2022 · Systematic Review, Network Meta-Analysis
- Real-world experience with cenobamate: A systematic review and meta-analysis.
Makridis KL, Kaindl AM · Seizure 2023 · Meta-Analysis, Systematic Review
- Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study.
Sperling MR, Klein P, Aboumatar S, et al. · Epilepsia 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Sk Life
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.